Page last updated: 2024-11-04

arabinose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pentopyranose : Any pentose that exists in the pyranose form. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID229
CHEMBL ID14343
CHEBI ID131402
CHEBI ID25901
SCHEMBL ID933026
MeSH IDM0001644
PubMed CID439195
CHEMBL ID1357418
CHEBI ID17535
CHEBI ID30849
SCHEMBL ID359263
MeSH IDM0001644

Synonyms (106)

Synonym
arabinose-
OPREA1_189511
nsc76347
nsc93887
smr000857162
MLS001332430
MLS001332429
pentopyranose
nsc407015
STK366962
57066-79-2
nsc-164936
nsc164936
NCIOPEN2_003813
4AB5584D-7A79-4737-B016-F7CB0A018088
|a-d-xylopyranose
oxane-2,3,4,5-tetrol
pentose ,
AKOS000120061
50986-18-0
oxane-2,3,4,5-tetrol, (3s,4r,5r)-
BBL001155
CHEMBL14343
HMS2234M04
FT-0674419
FT-0627692
FT-0638798
(3r,4s,5r)-tetrahydro-2h-pyran-2,3,4,5-tetraol
HMS3371M01
478506-29-5
MLS003106569
MLS006011474
l(+)arabinose; amidosulfonic acid; 4-dimethylaminobenzalrhodanine;(2s,3r,4s,5s)-tetrahydro-2h-pyran-2,3,4,5-tetraol
SCHEMBL933026
|a-?d-?xylopyranose
SRBFZHDQGSBBOR-UHFFFAOYSA-N
pentopyranoside
1132639-46-3
d,l-arabinose
d-[2,5-13c2]ribose
d-[1,2-13c2]ribose
d-[3-2h]ribose
SY013750
SY013715
beta-d-ribopyranose (9ci)
alpha-l-lyxopyranose (9ci)
alpha-d-arabinopyranose (9ci)
BCP05227
l-arabinose;l-arabinopyranose
SY112851
VS-00832
d-[5-13c]ribose
d-[4-2h]ribose
478506-58-0
DTXSID60859031 ,
d-[2-2h]ribose
mfcd20731172
an arabinopyranose
holzzucker; losan;alpha-xylose
SY074695
SB47708
SB45272
SB45434
SB47704
SB46706
EN300-20117
dtxcid701375352
dtxcid60209350
chebi:131402
chebi:25901
AC-14130
ARA ,
CHEBI:17535 ,
ARABINOSE ,
l-arabinose ,
l-arabinopyranose ,
C00259
NCGC00166074-01
A-8240
E0E89A5B-75E5-437B-953E-16E75EE7AEF2
arabinose l-form
(3r,4s,5s)-oxane-2,3,4,5-tetrol
A808696
(3r,4s,5s)-tetrahydropyran-2,3,4,5-tetrol
A842354
l(+)-arabinose
AKOS006240450
einecs 201-767-6
arabinopyranose
CHEMBL1357418
(3r,4s,5s)-tetrahydro-2h-pyran-2,3,4,5-tetraol
DTXSID5052836 ,
SCHEMBL359263
arabinopyranoside
l-ara
l-arabinopyranoside
l(+)-pectinose
mfcd00006609
AS-39893
Q27102447
dtxcid7019733
wurcs=2.0/1,1,0/(a211h-1x_1-5)/1/
chebi:30849
dtxcid7031379
arabinose, l-(van)
l-arabino-pentose

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" SDS-PAGE of the toxic fraction showed a single band with a Mr of about 150,000, and after dithiothreitol treatment, two bands with Mr of 100,000 and 50,000."( Detection of neutral sugars in purified type G botulinum progenitor toxin and the effects of some glycolytic enzymes on its molecular dissociation and oral toxicity.
Miyata, T; Nukina, M; Sakaguchi, G; Sakaguchi, S, 1991
)
0.28
"In seeking to develop a safe fowl typhoid (FT) vaccine, a novel candidate lacking cpxR, lon, and asd Salmonella Gallinarum (SG) genes was constructed with the plasmid-containing araC::P(araBAD)::asd system."( Safety evaluation and immunogenicity of arabinose-based conditional lethal Salmonella Gallinarum mutant unable to survive ex vivo as a vaccine candidate for protection against fowl typhoid.
Chaudhari, AA; Kim, SW; Lee, JH; Matsuda, K, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
"To further characterize the properties of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB), a recently described novel and potent inhibitor of glycogen phosphorylase and potential anti-diabetic agent, we have determined its pharmacokinetic properties in rats, dogs and mice and compared these to its pharmacodynamic anti-hyperglycaemic efficacy."( Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice.
Andersen, JV; Mackay, P; McCormack, JG; Ynddal, L, 2003
)
0.32

Bioavailability

L-Arabinose is a natural, poorly absorbed pentose that selectively inhibits intestinal sucrase activity. The higher bioavailability of arabinose and xylose after pasta intake coincided with a lower rate of appearance of glucose and amino acids.

ExcerptReferenceRelevance
"Influence of the pH on the absorption rate of sugars by rat intestine in vivo has been revised by means of a technique for intestinal lumen perfusion with 1 minute absorption periods."( Effect of the pH on intestinal absorption of sugars in vivo.
Lluch, M; Ortiz, M; Ponz, F, 1979
)
0.26
"L-Arabinose is a natural, poorly absorbed pentose that selectively inhibits intestinal sucrase activity."( L-arabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats.
Hizukuri, S; Iritani, N; Kimura, T; Osaki, S; Sugimoto, T, 2001
)
0.31
" Bioavailability was calculated as F=AUC by gavage/AUC by injection, where AUC is the area under the curve of plasma probe concentration vs."( Intestinal passive absorption of water-soluble compounds by sparrows: effect of molecular size and luminal nutrients.
Caviedes-Vidal, E; Chediack, JG; Fasulo, V; Karasov, WH; Yamin, LJ, 2003
)
0.32
" Such microbial degradation may be an important factor affecting the bioavailability of dietary FA."( Digestion and absorption of ferulic acid sugar esters in rat gastrointestinal tract.
Egashira, Y; Sanada, H; Zhao, Z, 2003
)
0.32
") administration; the oral bioavailability was 89%."( Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice.
Andersen, JV; Mackay, P; McCormack, JG; Ynddal, L, 2003
)
0.32
" The higher bioavailability of arabinose and xylose after pasta intake coincided with a lower rate of appearance of glucose and amino acids."( Metabolic Profiling Reveals Differences in Plasma Concentrations of Arabinose and Xylose after Consumption of Fiber-Rich Pasta and Wheat Bread with Differential Rates of Systemic Appearance of Exogenous Glucose in Healthy Men.
Bijlsma, S; Bobeldijk, I; Eelderink, C; Pantophlet, AJ; Priebe, MG; Stroeve, JH; van Stee, L; Vonk, RJ; Wopereis, S, 2017
)
0.46
" Specifically, l-arabinose, a monosaccharide that is poorly absorbed in the gut and inhibits intestinal sucrase, suppresses diet-induced obesity in mice in the presence of sucrose."( Cooperative action of gut-microbiota-accessible carbohydrates improves host metabolic function.
Akiyama, M; Ejima, R; Fujimura, Y; Gondo, M; Hase, K; Hattori, K; Honme, Y; Inohara, N; Kim, YG; Kimizuka, T; Kimura, I; Núñez, G; Ozaki, S; Sato, H; Seki, N; Suematsu, M; Sugiura, Y; Tomioka, S; Uchiyama, J; Yakabe, K; Yamaguchi, G, 2022
)
0.72

Dosage Studied

The objective was to investigate the dose-response effects of l-arabinose on intestinal sucrase activity in vitro and glucose tolerance, appetite, and energy intake in humans. In intact animals, the fractional absorption of orally dosed l-Arabinose (Mr 150) was 82% in M.

ExcerptRelevanceReference
" Analysis of the dose-response data by a double reciprocal plot method indicated that the antagonism was competitive."( Deoxyadenosine antagonism of the antiviral activity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosylhypoxanthine.
Drach, JC; Shipman, C; Smith, SH, 1978
)
0.26
" All the wines were mutagenic in the absence of mammalian microsomal activation (S9 mix) and/or glycosidase activities with the exception of one rosé wine which gave a clear dose-response relationship, although its mutagenic potency was considered statistically nonsignificant."( Direct-acting mutagenic activity in white, rosé, and red wines with the Ara test of Salmonella typhimurium.
Ariza, RR; Pueyo, C; Serrano, A, 1992
)
0.28
" All flavonoids gave a dose-response relationship and induced a number of AraR mutants considered statistically significant."( Study on the mutagenic activity of 13 bioflavonoids with the Salmonella Ara test.
Alejandre-Durán, E; Alonso-Moraga, A; Jurado, J; Pueyo, C, 1991
)
0.28
" Administration of ara-A by several different intermittent dosage regimens showed that change in pattern of response in terms of survivors appears to be influenced more by total amount of drug administered than by schedule or duration of drug treatment."( Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine.
McLean, IW; Miller, FA; Sloan, BJ, 1973
)
0.25
" Ara-A and IUdR, when administered intraperitoneally by several different dosage schedules, reduced the severity of cutaneous herpetic lesions and the incidence of paralysis and increased significantly the number of survivors."( Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds.
Brady, E; Friedman-Kien, AE; Klein, RJ, 1974
)
0.25
" This effect could be important in vivo where levels of ara-A oscillate with dosing schedule."( Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity.
Drach, JC; Novack, J; Schwartz, PM; Shipman, C, 1984
)
0.27
" Estimates of reagent concentrations in brain interstitial fluid 30 min after dosing the animals indicated that both an extremely high dose of DyTTHA3- and severe disruption of the BBB would be required to shift the resonance frequency of extracellular Na+ appreciably."( Diffusion into rat brain of contrast and shift reagents for magnetic resonance imaging and spectroscopy.
Foster, DO; Preston, E,
)
0.13
" A high fumarate level resulted in a dose-response curve linking bias and cytoplasmic CheY concentration that was offset but with a slope similar to that for a low fumarate level."( Regulation of switching frequency and bias of the bacterial flagellar motor by CheY and fumarate.
Eisenbach, M; Marwan, W; Montrone, M; Oesterhelt, D, 1998
)
0.3
" By inducing the biosensor with varying amounts of L-arabinose and a constant amount of IPTG, it was possible to obtain a dose-response curve for L-arabinose, together with a constant production of EYFP, which allowed for a dynamic evaluation of the metabolic activity of the cell."( Internal response correction for fluorescent whole-cell biosensors.
Daunert, S; Feliciano, J; Michelini, E; Mirasoli, M; Roda, A, 2002
)
0.31
" DAB was very rapidly cleared in mice; nevertheless, a dose-dependent reduction of blood glucose of up to 9 mmol/l was seen in diabetic ob/ob mice dosed subcutaneously, with statistically significant effects evident from 30 to 120 min."( Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice.
Andersen, JV; Mackay, P; McCormack, JG; Ynddal, L, 2003
)
0.32
"05, dosage of 200 mg/kgd body weight) in peripheral lymphocytes compared to the irradiated control."( Water-soluble polysaccharides from Angelica sinensis (Oliv.) Diels: Preparation, characterization and bioactivity.
Gu, X; Li, D; Sun, Y; Tang, J, 2005
)
0.33
" Evidence for dose-response of bean and hibiscus extracts is reported."( Inhibition by natural dietary substances of gastrointestinal absorption of starch and sucrose in rats and pigs: 1. Acute studies.
Bagchi, D; Echard, B; Preuss, HG; Stohs, S, 2007
)
0.34
"The objective was to investigate the dose-response effects of l-arabinose on intestinal sucrase activity in vitro and glucose tolerance, appetite, and energy intake in humans."( The effects of L-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans.
Andersen, JR; Bukhave, K; Hels, O; Holst, JJ; Krog-Mikkelsen, I; Tetens, I, 2011
)
0.37
" KNPS was found non-toxic toward human lymphocyte up to the dosage of 100 μg/ml."( Structural elucidation and biological studies of a novel exopolysaccaride from Klebsiella pneumoniae PB12.
Chakraborty, R; Chattopadhyay, S; Islam, SS; Maity, P; Mandal, AK; Roy, S; Sen, IK, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
L-arabinoseThe L-enantiomer of arabinose.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
L-Arabinose Degradation I47
UDP-L-arabinose biosynthesis and transport616
UDP-L-arabinose biosynthesis (salvage pathway)07

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.01190.044717.8581100.0000AID485294
IDH1Homo sapiens (human)Potency10.32250.005210.865235.4813AID686970
gemininHomo sapiens (human)Potency15.84890.004611.374133.4983AID624297
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency19.95260.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1713539Inhibition of diphenolase activity of mushroom tyrosinase using L-DOPA substrate2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
ArgTX-636, a polyamine isolated from spider venom: A novel class of melanogenesis inhibitors.
AID1711518Growth inhibition of Caenorhabditis elegans N2 L1 larvae under monoxenic condition with Escherichia coli food assessed as reduction in body size at 42 mM incubated for 72 hrs by microscopic method relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Growth inhibitory effect of D-arabinose against the nematode Caenorhabditis elegans: Discovery of a novel bioactive monosaccharide.
AID35662Binding affinity against Amiloride-sensitive amine oxidase [ABP(P254G)]2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID30428Compound was tested for inhibition of Human acrosin by aldopentoses1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID38895Binding affinity against Arabinose binding protein of the compound2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID35661Binding affinity against Amiloride-sensitive amine oxidase [ABP(M108L)]2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,248)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901456 (44.83)18.7374
1990's289 (8.90)18.2507
2000's566 (17.43)29.6817
2010's743 (22.88)24.3611
2020's194 (5.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.08 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index115.93 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials12 (0.36%)5.53%
Reviews0 (0.00%)6.00%
Reviews67 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies4 (0.12%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other3,270 (97.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]